Natera
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invas...
Latest News
1 day ago · marketbeat.com
Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve reimbursement.
2 days ago · marketbeat.com
Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”Natera NASDAQ: NTRA CFO Mike Brophy said the company's newly announced $6 billion revenue target for 2029 is achievable with strong execution, as he outlined expectations for its Signatera cancer test and defended the immediate transition to a new CEO.
5 days ago · seekingalpha.com
Natera, Inc. (NTRA) Presents at 2026 UBS Global Healthcare Conference TranscriptNatera, Inc. ( NTRA ) 2026 UBS Global Healthcare Conference November 9, 2026 8:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good morning, everybody.
5 days ago · seekingalpha.com
Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference TranscriptNatera, Inc. ( NTRA ) 8th Annual Wolfe Research Healthcare Conference November 10, 2026 12:00 PM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Paige Chamberlain - Wolfe Research, LLC Presentation Paige Chamberlain Wolfe Research, LLC Hi, everyone. Thanks for being here.
7 days ago · zacks.com
Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 OutlookNTRA targets $6B in revenues by 2029 as Signatera testing surges, reimbursement expands and higher investments support its long-term growth strategy.
8 days ago · zacks.com
NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View UpNatera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.
10 days ago · seekingalpha.com
Natera, Inc. (NTRA) Q3 2026 Earnings Call TranscriptNatera, Inc. ( NTRA ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - GM of Oncology and Early Cancer Detection & Chief Medical Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to Natera's Second (sic) [ Third ] Quarter 2026 Earnings Conference Call.
11 days ago · benzinga.com
Natera Stock Plummets After Mixed Q3 FinancialsNatera Inc. (NASDAQ:NTRA) shares are plunging Friday after reporting mixed third-quarter results, with revenue and guidance beating estimates while the loss per share came in wider than analysts expected. Here's what you should know.
11 days ago · marketbeat.com
What Natera (NTRA) Said on Its Q3 Earnings CallNatera NASDAQ: NTRA raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in leadership.
11 days ago · businesswire.com
Natera Reports Third Quarter 2026 Financial ResultsAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026. Recent Financial Highlights Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%. Generated a gross margin1 of 64.7% in the third quarter of 2026, compared to a gross margin1 of 64.9% in the third q.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NTRA